 BERKELEY, Calif., March 08, 2022 GLOBE NEWSWIRE -- Caribou Biosciences, Inc. Nasdaq: CRBU, a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclinical data from CB-011, its allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma rr MM, will be presented as a poster at the upcoming American Association for Cancer Research AACR Annual Meeting 2022, held April 8-13, 2022 in New Orleans. 